{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-23-000907","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.051789+00:00","generated_at":"2026-06-07T15:30:52.227925+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tonix Pharmaceuticals enters $11M term loan with JGB entities; reviews Phase 2 migraine data","bullets":["$11.0M 36-month term loan from JGB Capital, JGB Partners, JGB (Cayman) Cornish Rock; interest at Prime+3.5% floor 12%.","Loan secured by R&D center in Frederick, MD, and Advanced Development Center in North Dartmouth, MA, and deposit accounts.","Prepayment premium: $700K if paid by Dec 2024, $1M if by Dec 2025, $1.3M thereafter.","Company analyzing Phase 2 proof-of-concept results for TNX-1900 (intranasal potentiated oxytocin) for chronic migraine; expects completion by late Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-23-000907","json":"https://secwatch.observer/filing/0001999371-23-000907.json","markdown":"https://secwatch.observer/filing/0001999371-23-000907.md","text":"https://secwatch.observer/filing/0001999371-23-000907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/0001999371-23-000907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/tnxp_8k-120823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:30:52.227925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9feb726b86933f82e127a3ad61ef5187d209de6","claim":"Tonix Pharmaceuticals Holding Corp. incurred term loan of $11.0 million with JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd. at greater of (i) the Prime Rate plus 3.5% and (ii) 12% maturing 36-month.","evidence_excerpt":"as administrative agent and collateral agent for the Lenders (in such capacity, “ JGB Agent ”) for a 36-month term loan (the “ Term Loan ”) in the aggregate principal amount of $11.0 million. Interest Rate All outstanding amounts under the Term Loan bear interest at a fluctuating per annum interest rate (the “ Applicable Rate ”) equal to the greater of (i) the Prime","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/0001999371-23-000907-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$11.0 million"},{"label":"Counterparty","value":"JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd."},{"label":"Rate","value":"greater of (i) the Prime Rate plus 3.5% and (ii) 12%"},{"label":"Maturity","value":"36-month"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"1b6d893e9a76bf2390878c9359380f4e4e07cabd","claim":"Tonix Pharmaceuticals Holding Corp. entered into Loan and Guaranty Agreement with JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and JGB Collateral LLC valued at aggregate principal amount of $11.0 million (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, Tonix Pharmaceuticals Holding Corp. (the “ Company ”) entered into a Loan and Guaranty Agreement (the “ Loan Agreement ”) by and among the Company, Krele LLC, a wholly-owned subsidiary of Tonix Pharmaceuticals, Inc. (“ Tonix ”), a wholly-owned subsidiary of the Company (“ Krele ”), Jenner Institute, LLC, a wholly-owned subsidiary of Tonix (“ Jenner ”), Tonix R&D Center, a wholly-owned subsidiary of Tonix (“ Tonix R&D ”, and together with the Company, Krele and Jenner, the “ Loan Parties ”), JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and any other lender from time to time party hereto (collectively, the “ Lenders ”), and JGB Collateral LLC, as administrative agent and collateral agent for the Lenders (in such capacity, “ JGB Agent ”) for a 36-month term loan (the “ Term Loan ”) in the aggregate principal amount of $11.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937123000907/0001999371-23-000907-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and JGB Collateral LLC"},{"label":"Value","value":"aggregate principal amount of $11.0 million"},{"label":"Effective","value":"2023-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}